Zobrazeno 161 - 167
of 167
pro vyhledávání: ''
Autor:
James Joseph Gibbons, Joel W. Neal, Christine M. Lovly, Gary Dukart, Saiama N. Waqar, Jon P. Gockerman, K. Harrow, Jeffrey R. Infante, Heather A. Wakelee, Corey A. Carter, George R. Blumenschein, Chris Liang, Leora Horn, Karen L. Reckamp
Publikováno v:
Cancer Research. 76:CT088-CT088
Background: X-396 is a novel, potent anaplastic lymphoma kinase (ALK) small molecule tyrosine kinase inhibitor (TKI) with additional activity against MET, ABL, Axl, EPHA2, LTK, ROS1 and SLK. It has demonstrated significant anti-tumor activity in both
Autor:
Funda Meric-Bernstam, Cristina Saura, Feng Xu, S.J. Garza, David M. Hyman, Alshad S. Lalani, David B. Solit, Shanu Modi, Sherene Loi, H Joensuu, J. Baselga, Sarina Anne Piha-Paul, Jordi Rodon, Geoffrey I. Shapiro, Igor Puzanov, Aphrothiti J. Hanrahan, Richard E. Cutler, Richard A. Bryce
Publikováno v:
Cancer Research. 76:PD5-05
Background: Somatic ERBB2 (HER2) mutations occur in approximately 2% of patients with breast cancer and are found in a predominantly mutually exclusive manner with ERBB2 amplification. These mutations result in increased signaling and oncogenic trans
Autor:
Z. Tang, T. Paquet-Luzy, M. Martin, M. De Laurentiis, G. Jerusalem, K. L. Blackwell, Xavier Pivot, Peter A. Fasching, Karen Rodriguez Lorenc, DJ Slamon, Francisco J. Esteva
Publikováno v:
Cancer Research. 76:OT2-01
Background: Endocrine therapy (ET) is the predominant first-line treatment for HR+, HER2– aBC; however, resistance eventually occurs in a large number of cases. Dysregulation of the cyclin D–cyclin dependent kinase (CDK)4/6–inhibitor of CDK4 (I
Autor:
S-A Im, M. Campone, J. Baselga, Yoshinori Ito, M. De Laurentiis, Agnieszka Jagiełło-Gruszfeld, J. Cortes, Walter Jonat, Patrick Urban, Cristian Massacesi, S Hurvitz, Noriyuki Masuda, E. di Tomaso, H. Iwata, Soulef Hachemi, CL Arteaga, Ahmad Awada, L-M Tseng, Zefei Jiang, S Le Mouhaër, S Chia, Mark Clemons, Barbara Pistilli
Publikováno v:
Cancer Research. 76:S6-01
Background: PI3K pathway activation is a hallmark of hormone receptor-positive (HR+) BC cells resistant to endocrine therapy (ET). Preclinical and early clinical data suggest that combining the pan-PI3K inhibitor BUP (BKM120) with ET may provide clin
Autor:
Rachel Wuerstlein, Cornelia Liedtke, Michael Braun, U. Nitz, Astrid Kiermaier, Nadia Harbeck, J. Tio, H.H. Kreipe, Helmut Forstbauer, J. Potenberg, S. de Haas, Bahriye Aktas, Ronald E. Kates, Anke Kleine-Tebbe, O Gluz, Matthias Christgen, Doris Augustin, Claudia Schumacher, S. Kuemmel, Stefan Kraemer
Publikováno v:
Cancer Research. 76:S5-03
Background: In HER2+ early breast cancer (eBC) pCR rates after standard neoadjuvant chemo- + anti-HER2 therapy differ according to hormone-receptor (HR) status. Molecular analysis reveals HER2+/HR+ BC as a distinct entity within HER2+ BC. The ADAPT H
Autor:
Steven Gendreau, Stephen T. Johnston, Ian E. Krop, Mika K. Derynck, J Qui, Peter Schmid, Kimberly Walter, G. Hampton, Lukas C. Amler, Mark R. Lackner, Jill M. Spoerke, Iris T. Chan
Publikováno v:
Cancer Research. 76:PD6-03
Background: Mutations in the ligand binding domain of the estrogen receptor gene (ESR1) have been associated with resistance to AI therapy in pts with ER+ breast cancer. To assess if ESR1 status has prognostic or predictive significance in the post-A
Autor:
Alissa Poh
Publikováno v:
Cancer Discovery. 6:4-4
In the last few weeks, the FDA approved three new therapies for multiple myeloma: ixazomib, the first oral proteasome inhibitor; and daratumumab and elotuzumab, two monoclonal antibodies that target CD38 and SLAMF7, respectively.